Pfizer's COVID-19 mRNA Product is 13-Times Less Effective at Preventing Infection With SARS-CoV-2 than Naturally Acquired Immunity!

Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

1.1K

•

Pfizer's COVID-19 mRNA Product is 13-Times Less Effective at Preventing Infection With SARS-CoV-2 than Naturally Acquired Immunity! (viralimmunologist.substack.com)

Here is the take-home message as concluded by the authors in the discussion section of the paper:

“Our analysis demonstrates that SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for a symptomatic disease as well.”

This study represents a critical head-to-head comparison of naturally acquired immunity to SARS-CoV-2 versus the SARS-CoV-2-specific immune response conferred by the two doses of the Pfizer-BioNTech mRNA product that was required to obtain the so-called ‘fully vaccinated’ status. This largely occurred in the context of the wave of cases that was dominated by the Delta variant. People whose first exposure was to natural infection with SARS-CoV-2 were compared to those whose first exposure was via receipt of Pfizer’s mRNA product. In other words, which source of ‘immunity’ could confer the best long-term protection against infection with SARS-CoV-2, which is the virus that causes COVID-19 in some people.

Here is the take-home message as concluded by the authors in the discussion section of the paper: “Our analysis demonstrates that SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for a symptomatic disease as well.” This study represents a critical head-to-head comparison of naturally acquired immunity to SARS-CoV-2 versus the SARS-CoV-2-specific immune response conferred by the two doses of the Pfizer-BioNTech mRNA product that was required to obtain the so-called ‘fully vaccinated’ status. This largely occurred in the context of the wave of cases that was dominated by the Delta variant. People whose first exposure was to natural infection with SARS-CoV-2 were compared to those whose first exposure was via receipt of Pfizer’s mRNA product. In other words, which source of ‘immunity’ could confer the best long-term protection against infection with SARS-CoV-2, which is the virus that causes COVID-19 in some people.